Recent Updates
Recently added Catalysts
RIGL Positive Sentiment Score: 65/100

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Monday, July 7, 2025 1 min read
Key Takeaway: Rigel Pharmaceuticals, Inc. has announced the granting of awards under its Inducement Plan, following NASDAQ Listing Rule 5635(c)(4). The company has allocated 23,075 stock options and restricted stock units to ten non-executive employees, which will vest over four years with a one-year cliff. This step reflects Rigel's strategy to incentivize and attract talent within the biotechnology sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel has granted stock options and restricted stock units as an inducement for new employees.
  • The grant includes a significant number of stock options (23,075) to support employee retention.
  • This move indicates Rigel's commitment to attracting talent in the biotechnology space.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,075 stock options and restricted stock units to 10 non-executive employees vesting over four years with a one-year cliff.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
SOURCE Rigel Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What did Rigel Pharmaceuticals announce on July 7, 2025?

Rigel announced the granting of stock options and restricted stock units to employees.

How many employees received stock awards from Rigel?

Awards were granted to 10 non-executive employees.

What is the vesting period for Rigel's stock options?

The stock options vest over four years with a one-year cliff.

When was Rigel Pharmaceuticals founded?

Rigel was founded in 1996 and is based in South San Francisco.

What type of therapeutics does Rigel focus on?

Rigel focuses on therapies for hematologic disorders and cancer.

Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals NASDAQ inducement plan stock options biotechnology
Last updated: Jul 7, 2025